White Darrell E, Zhao Yang, Jayapalan Hemalatha, Machiraju Pattabhi, Periyasamy Ramu, Ogundele Abayomi
SkyVision Centers, Westlake, OH, USA.
Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.
Clin Ophthalmol. 2020 Mar 19;14:875-883. doi: 10.2147/OPTH.S233194. eCollection 2020.
To assess patient satisfaction among current and former users of the anti-inflammatory topical medications, cyclosporine A 0.05% (CYC) and lifitegrast 5.0% (LIF), for the management of dry eye disease (DED).
Patients with DED were recruited via physician referral to participate in a survey. Current users of CYC or LIF were asked to rate their experience in terms of satisfaction, side effects, and limitation of activities. Switchers of CYC to LIF or LIF to CYC were asked to rate the importance of potential reasons for switching.
Surveys were completed by 207 patients currently treated with CYC (n=98), LIF (n=96), or other DED medications (n=13). Although overall satisfaction with current treatment was high, current users of CYC and LIF reported ineffective relief of DED symptoms (31% and 22%, respectively) and dissatisfaction with the time to onset of effect (29% and 11%). Substantial proportions of patients reported 'sometimes', "usually", or 'always' experiencing the following side effects: burning sensation (72% CYC, 64% LIF), itching (43% CYC, 44% LIF), altered sensation of taste (21% CYC, 56% LIF), blurred vision (37% CYC, 50% LIF), and discharge (28% CYC, 30% LIF). Of the 30 switchers of CYC to LIF and 31 switchers of LIF to CYC, the majority reported inability to relieve DED symptoms as a very or extremely important switching reason. Despite switching, one in four patients were somewhat dissatisfied or dissatisfied with their current medication, with 37% of patients reporting ineffective symptom relief.
Although the rate of overall satisfaction was generally high with both LIF and CYC, many patients were unable to achieve effective symptom relief and commonly experienced side effects. The proportion of patients who were dissatisfied and/or unable to achieve effective symptom relief even after switching suggests the need for additional treatment options for managing DED.
评估抗炎局部用药环孢素A 0.05%（CYC）和lifitegrast 5.0%（LIF）的当前及既往使用者对干眼症（DED）治疗的患者满意度。
通过医生转诊招募DED患者参与一项调查。CYC或LIF的当前使用者被要求对其在满意度、副作用及活动受限方面的体验进行评分。CYC换用LIF或LIF换用CYC的患者被要求对换药潜在原因的重要性进行评分。
207例患者完成了调查，其中目前接受CYC治疗的患者有98例，接受LIF治疗的患者有96例，接受其他DED药物治疗的患者有13例。尽管对当前治疗的总体满意度较高，但CYC和LIF的当前使用者均报告DED症状缓解效果不佳（分别为31%和22%），且对起效时间不满意（分别为29%和11%）。相当比例的患者报告“有时”“通常”或“总是”出现以下副作用：烧灼感（CYC为72%，LIF为64%）、瘙痒（CYC为43%，LIF为44%）、味觉改变（CYC为21%，LIF为56%）、视力模糊（CYC为37%，LIF为50%）和分泌物增多（CYC为28%，LIF为30%）。在30例从CYC换用LIF和31例从LIF换用CYC的患者中，大多数报告无法缓解DED症状是非常重要或极其重要的换药原因。尽管换了药，但四分之一的患者对其当前用药仍有些不满意或不满意，37%的患者报告症状缓解效果不佳。
尽管LIF和CYC的总体满意度普遍较高，但许多患者无法有效缓解症状，且常出现副作用。即使换药后仍不满意和/或无法有效缓解症状的患者比例表明，需要有更多治疗选择来管理DED。
